Ipsen S.A./€IPN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Ipsen S.A.
Ipsen S.A. is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. The company focuses on the development and commercialization of innovative medicines in targeted therapeutic areas such as oncology, neuroscience, and rare diseases. Ipsen's key products include Somatuline, a treatment for neuroendocrine tumors and acromegaly, and Dysport, used for movement disorders and aesthetic indications. Founded in 1929 by Henri Beaufour, Ipsen has since expanded its presence worldwide, with a strategic emphasis on specialty care and the development of differentiated products. The company leverages its scientific expertise and research capabilities to sustain its competitive position in the biopharmaceutical industry.
Ticker
€IPN
Sector
Primary listing
PAR
Employees
5,535
Headquarters
Website
Ipsen S.A. Metrics
BasicAdvanced
€13bn
29.47
€5.32
0.33
€1.60
1.02%
Price and volume
Market cap
€13bn
Beta
0.33
52-week high
€173.00
52-week low
€100.20
Average daily volume
2.6k
Dividend rate
€1.60
Financial strength
Current ratio
1.961
Quick ratio
1.688
Long term debt to equity
17.252
Total debt to equity
20.391
Dividend payout ratio (TTM)
26.20%
Interest coverage (TTM)
122.26%
Profitability
EBITDA (TTM)
1,340.1
Gross margin (TTM)
80.89%
Net profit margin (TTM)
11.29%
Operating margin (TTM)
26.14%
Effective tax rate (TTM)
23.11%
Revenue per employee (TTM)
€710,000
Management effectiveness
Return on assets (TTM)
9.14%
Return on equity (TTM)
10.44%
Valuation
Price to earnings (TTM)
29.474
Price to revenue (TTM)
3.298
Price to book
3.01
Price to tangible book (TTM)
9.22
Price to free cash flow (TTM)
15.993
Free cash flow yield (TTM)
6.25%
Free cash flow per share (TTM)
9.804
Dividend yield (TTM)
1.02%
Forward dividend yield
1.02%
Growth
Revenue change (TTM)
9.92%
Earnings per share change (TTM)
28.19%
3-year revenue growth (CAGR)
7.57%
10-year revenue growth (CAGR)
9.96%
3-year earnings per share growth (CAGR)
-12.00%
10-year earnings per share growth (CAGR)
8.77%
3-year dividend per share growth (CAGR)
5.27%
10-year dividend per share growth (CAGR)
5.12%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs